An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
| Autor: | Mukul Rastogi, Diana A. Payawal, Jose D. Sollano, Zahid Yasin Hashmi, Do Duy Cuong, Michael Charlton, Khin Maung Win, Wattana Sukeepaisarnjaroen, Kaushal Madan, Khin Pyone Kyi, Kyaw Soe Tun, Pham Tran Dieu Hien, Win Naing, Tawesak Tanwandee, Rosmawati Mohamed, Bekhbold Dashtseren, Cosmas Rinaldi A Lesmana, Ganbolor Jargalsaikhan, Pham Thi Thu Thuy, K Singh, Rino Alvani Gani, Altaf Alam, Akash Shukla, Mohd. Salih, Ian Homer Y. Cua, Davadoorj Duger, Neeraj Saraf, Teerha Piratvisuth |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Hepatitis B virus Asia Review medicine.disease_cause Tenofovir alafenamide Antiviral Agents law.invention 03 medical and health sciences 0302 clinical medicine Hepatitis B Chronic Randomized controlled trial law Internal medicine Drug Resistance Viral medicine Humans Tenofovir Randomized Controlled Trials as Topic Alanine Nucleoside analogue business.industry Incidence (epidemiology) Gastroenterology Lamivudine Entecavir Hepatology 030220 oncology & carcinogenesis Nucleoside analogs 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Journal of Gastroenterology |
| ISSN: | 1435-5922 0944-1174 |
| Popis: | Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key interventions for curbing HBV infection and associated morbidity in Asia. However, there are some challenges to the use of ETV and TDF; while ETV is associated with high resistance in lamivudine (LAM)-exposed (especially LAM-refractory) patients; bone and renal safety issues are a major concern with TDF. Hence, a panel of twenty-eight expert hepatologists from Asia convened, reviewed the literature, and developed the current expert opinion-based review article for the use of TAF in the resource-constrained settings in Asia. This article provides a comprehensive review of two large, phase 3, double-blind, randomized controlled trials of TAF versus TDF in HBeAg-negative (study 0108) and HBeAg-positive (study 0110) chronic HBV patients (> 70% Asians). These studies revealed as follows: (1) non-inferiority for the proportion of patients who had HBV DNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink